. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: J Surg Oncol. 2019 May 6;120(2):132–141. doi: 10.1002/jso.25492

Table 1.

Patient Characteristics, Patients with cT1–4c, cN1–3 Invasive Lobular Carcinoma, National Cancer Data Base, 2004–2013 (N=15,573)

	All patients (N=15,573) n (%)^a	NACT (N=5551) n (%)^a	ACT (N=10,022) n (%)^a	P-Value^e
Age (years)				<0.001
≥50	10,862 (69.7%)	3450 (62.2%)	7412 (74.0%)
<50	4711 (30.3%)	2101 (37.8%)	2610 (26.0%)
Median (IQR)	56.0 (48.0–64.0)	53.0 (46.0–61.0)	58.0 (49.0–66.0)	<0.001
Gender				0.98
Female	15,497 (99.5%)	5524 (99.5%)	9973 (99.5%)
Male	76 (0.5%)	27 (0.5%)	49 (0.5%)
Race				0.03
White	13,159 (84.5%)	4655 (83.9%)	8504 (84.9%)
Black	1714 (11.0%)	655 (11.8%)	1059 (10.6%)
Other	533 (3.4%)	176 (3.2%)	357 (3.6%)
Ethnicity				0.009
Hispanic	942 (6.0%)	374 (6.7%)	568 (5.7%)
Non-Hispanic	13,773 (88.4%)	4885 (88.0%)	8888 (88.7%)
Charlson/Deyo comorbidity score				<0.001
0	13,485 (86.6%)	4937 (88.9%)	8548 (85.3%)
1	1767 (11.3%)	538 (9.7%)	1229 (12.3%)
≥2	321 (2.1%)	76 (1.4%)	245 (2.4%)
Grade				0.01
1	2184 (14.0%)	721 (13.0%)	1463 (14.6%)
2	8243 (52.9%)	2771 (49.9%)	5472 (54.6%)
3	3325 (21.4%)	1207 (21.7%)	2118 (21.1%)
ER status				<0.001
ER+	14,079 (90.4%)	4790 (86.3%)	9289 (92.7%)
ER-	1233 (7.9%)	664 (12.0%)	569 (5.7%)
PR status				<0.001
PR+	12,085 (77.6%)	4060 (73.1%)	8025 (80.1%)
PR-	3146 (20.2%)	1370 (24.7%)	1776 (17.7%)
HER2 status^b				<0.001
HER2+	845 (10.9%)	432 (14.9%)	413 (8.5%)
HER2-	6620 (85.3%)	2354 (81.5%)	4266 (87.7%)
Tumor size				<0.001
<1 cm	676 (4.3%)	189 (3.4%)	487 (4.9%)
>1 to 2 cm	2753 (17.7%)	618 (11.1%)	2135 (21.3%)
>2 to 4 cm	5597 (35.9%)	1622 (29.2%)	3975 (39.7%)
>4 cm	6191 (39.8%)	2876 (51.8%)	3315 (33.1%)
Median (IQR)	3.5 (2.2–5.5)	4.5 (2.6–6.6)	3.0 (2.0–5.0)	<0.001
Clinical T stage				<0.001
1	3541 (22.7%)	614 (11.1%)	2927 (29.2%)
2	6911 (44.4%)	2073 (37.3%)	4838 (48.3%)
3	4313 (27.7%)	2246 (40.5%)	2067 (20.6%)
4	808 (5.2%)	618 (11.1%)	190 (1.9%)
Pathological T stage				<0.001
0	281 (1.8%)	269 (4.8%)	12 (0.1%)
1	3756 (24.1%)	1321 (23.8%)	2435 (24.3%)
2	6353 (40.8%)	1698 (30.6%)	4655 (46.4%)
3	3657 (23.5%)	1260 (22.7%)	2397 (23.9%)
4	442 (2.8%)	216 (3.9%)	226 (2.3%)
X	823 (5.3%)	609 (11.0%)	214 (2.1%)
Clinical N stage				<0.001
1	11,585 (74.4%)	4265 (76.8%)	7320 (73.0%)
2	2641 (17.0%)	880 (15.9%)	1761 (17.6%)
3	1347 (8.6%)	406 (7.3%)	941 (9.4%)
Pathological N stage				<0.001
0	1102 (7.1%)	874 (15.7%)	228 (2.3%)
1	6182 (39.7%)	1801 (32.4%)	4381 (43.7%)
2	4140 (26.6%)	1364 (24.6%)	2776 (27.7%)
3	3244 (20.8%)	964 (17.4%)	2280 (22.7%)
X	724 (4.6%)	445 (8.0%)	279 (2.8%)
Median no. of positive nodes (IQR)	4.0 (1.0–9.0)	3.0 (1.0–8.0)	4.0 (2.0–9.0)	<0.001
Median no. of nodes examined (IQR)	14.0 (9.0–19.0)	13.0 (8.0–18.0)	14.0 (9.0–20.0)	<0.001
Treated with endocrine therapy
Out of all patients	12,298 (79.0%)	4194 (75.6%)	8104 (80.9%)	<0.001
Out of ER+ or PR+ patients	12114 (77.8%)	4127 (74.3%)	7987 (79.7%)	0.91
Surgery type				<0.001
Lumpectomy	3561 (22.9%)	1008 (18.2%)	2553 (25.5%)
Mastectomy	12012 (77.1%)	4543 (81.8%)	7469 (74.5%)
Radiation
Post-lumpectomy^c	3139 (88.1%)	897 (89.0%)	2242 (87.8%)	0.33
Post-mastectomy^d	8496 (70.7%)	3492 (76.9%)	5004 (67.0%)	<0.001

Percentages are out of total population counts unless otherwise indicated, and may not add up to 100 due to rounding or missing values.

Percentages for HER2 status are out of patients diagnosed on or after 2010 (Overall N=7757, NACT N=2890, ACT N=4867).

Percentages represent rates of radiation receipt among patients receiving lumpectomy.

Percentages represent rates of radiation receipt among patients receiving mastectomy.

P-values for categorical variables are from chi-square tests. P-values from continuous variables are from pooled t-tests.

ACT: adjuvant chemotherapy. ER: estrogen receptor. HER2: human epidermal growth factor receptor 2. IQR: interquartile range. LN: lymph node. NACT: neoadjuvant chemotherapy. PR: progesterone receptor.